Â鶹´«Ã½

Â鶹´«Ã½ served as intellectual property counsel to Carna Health, an AI-enabled digital health company revolutionizing chronic disease prevention, in its partnership with Renalytix PLC (LSE: RENX) (OTCQB: RNLXY) to advance a novel, integrated approach to chronic kidney disease (CKD) management.

The collaboration combines Renalytix’s FDA-approved kidneyintelX.dkd™ test with Carna Health’s AI-enabled digital health platform to enable earlier identification of at-risk patients and more precise, risk-guided interventions. The integrated model is designed to help health systems shift from reactive treatment to proactive care, improving outcomes and reducing costs associated with late-stage kidney disease while supporting population-scale screening and personalized care pathways for patients with CKD and related cardio-kidney-metabolic (CKM) conditions.

Carna Health is a global AI-enabled digital health company addressing the silent, costly progression of CKM disease through population-scale screening and monitoring, predictive analytics, and care enablement. The intelligent platform aggregates point-of care and laboratory diagnostics and clinical data into a secure Patient 360, applying machine learning to identify undiagnosed risk, predict disease progression, and deliver actionable guidance to providers and patients, particularly in environments with limited specialist access.

Â鶹´«Ã½â€™s intellectual property team was led by partner Christopher McKenna and Aaron Maguregui.